CD8A and neoplasm: Accordingly, we evaluated the expression of the PODO447 tumor glycoepitope and the number of CD4+, CD8+ and CD3+ T cells and CD20+ B cells/plasma cells via multiplex IHC staining of Cohort D (Figure 4A).